Solid-State Behavior and Solubilization of Flash Nanoprecipitated Clofazimine Particles during the Dispersion and Digestion of Milk-Based Formulations
Open Access
- 30 April 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (6) , 2755-2765
Abstract
Clofazimine, a drug previously used to treat leprosy, has recently been identified as a potential new drug for the treatment for cryptosporidiosis: a diarrheal disease that contributes to 500 000 infant deaths a year in developing countries. Rapid dissolution and local availability of the drug in the small intestine is considered key to the treatment of the infection. However, the commercially available clofazimine formulation (Lamprene) is not well-suited to pediatric use, and therefore reformulation of clofazimine is desirable. Development of clofazimine nanoparticles through the process of flash nanoprecipitation (FNP) has been previously shown to provide fast and improved drug dissolution rates compared to clofazimine crystals and Lamprene. In this study, we investigate the effects of milk-based formulations (as possible pediatric-friendly vehicles) on the in vitro solubilization of clofazimine formulated as either lecithin- or zein/casein-stabilized nanoparticles. Milk and infant formula were used as the lipid vehicles, and time-resolved synchrotron X-ray scattering was used to monitor the presence of crystalline clofazimine in suspension during in vitro lipolysis under intestinal conditions. The study confirmed faster dissolution of clofazimine from all the FNP formulations after the digestion of infant formula was initiated, and a reduced quantity of fat was required to achieve similar levels of drug solubilization compared to the reference drug material and the commercial formulation. These attributes highlight not only the potential benefits of the FNP approach to prepare drug particles but also the fact that enhanced dissolution rates can be complemented by considering the amount of co-administered fat in lipid-based formulations to drive the solubilization of poorly soluble drugs.Keywords
Funding Information
- Division of Graduate Education (DGE-1656466)
- Australian Research Council (DP16, DP160102906, DE190100531)
- Bill and Melinda Gates Foundation (OPP1150755, OPP1160404)
This publication has 41 references indexed in Scilit:
- Structural Elucidation of Rapid Solution-Mediated Phase Transitions in Pharmaceutical Solids Using in Situ Synchrotron SAXS/WAXSMolecular Pharmaceutics, 2012
- Cryptosporidiosis in Children in Sub‐Saharan Africa: A Lingering ChallengeClinical Infectious Diseases, 2008
- Oral lipid-based formulationsAdvanced Drug Delivery Reviews, 2007
- Nitazoxanide: A New Thiazolide Antiparasitic AgentClinical Infectious Diseases, 2005
- Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification systemEuropean Journal of Pharmaceutics and Biopharmaceutics, 2004
- Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrineJournal of Pharmaceutical Sciences, 2004
- Mechanism for Rapid Self-Assembly of Block Copolymer NanoparticlesPhysical Review Letters, 2003
- Energy/Temperature Diagram and Compression Behavior of the Polymorphs of d-MannitolJournal of Pharmaceutical Sciences, 2000
- The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised ratInternational Journal of Pharmaceutics, 1994
- Subcellular compartmentalization of maize storage proteins in Xenopus oocytes injected with zein messenger RNAs.Journal of Cell Biology, 1981